πŸ‡ΊπŸ‡Έ FDA
Patent

US 11098283

T cells modified to overexpress c-Myb

granted A61KA61K2035/124A61K2239/38

Quick answer

US patent 11098283 (T cells modified to overexpress c-Myb) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2035/124, A61K2239/38, A61K2239/57, A61K40/11